IP Investors
CapLink tracks 53 active investors with a stated focus on IP, forming a well-defined sub-segment of the venture market.
The mix is led by VC, PE/Buy-Out and Corporate VC, alongside 4 other investor types. Deal coverage spans Pre-Seed through PE/Buy-out, with the largest concentration at Seed.
Investor headquarters cluster in Canada, United States, United Kingdom, Mexico and Netherlands, with activity across 194 countries in total. Ticket sizes range from roughly $10K to $200M, covering early angel cheques through to growth-stage rounds.
Use the pre-filtered database below to explore every IP investor on CapLink, or sign up to unlock contact details, ticket sizes and detailed investment criteria.
IP investor database
53 investors matched for IP. Sign up to unlock contact details and full profiles.
| Investor |
|---|
![]() IPSA is a private equity and venture capital firm specializing in seed, startup, early-stage, mid venture, later stage, growth capital, and pre-IPO investments. The firm prefers to invest in life sciences, Internet, telecommunications, biotechnology, medical, energy, chemistry, information and communications technology, water purification, natural resources, cleantech, capital goods, and distribution sectors. In life science sector it further invests in clinical-stage drug development, medical devices, drug delivery, and development services. In information and communications technology sector the firm invests with a focus in content, software, enabling technology, and infrastructure. In natural resources sector it invests further in exploration and production and renewable energy and clean technology. The firm seeks to invest in companies based in European Union with a focus on France, the U.K., Germany, the Netherlands, and Denmark and it also invest occasionally in companies based in North America. It seeks to invest in the first instance between €1 million ($1.33 million) and €5 million ($6.68 million) for a minority stake in the company. It seeks to invest in companies with revenues between €10 million ($13.37 million) and €100 million ($133.73 million). The firm prefers to be the lead or a co-lead investor in its portfolio companies. It seeks to hold a board seat in its portfolio companies. The firm exits from its portfolio companies through an IPO or trade sale within five years. The firm was formerly known as Innoven Partenaires S.A. IPSA was founded in 1997 and is based in Paris, France. |
IP Fund (АНО ППА «Центр инновационного развития») was created in 2016 as a platform to support strategic investments in technology companies, focusing on transactional monetization models, infrastructure solutions in finance, advertising, and education, as well as neurotechnology and MedTech. |
![]() IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital, networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in approximately 80 early-stage to mature businesses across three main sectors -- Life Sciences, Technology, and Cleantech. The Company is listed on the Main Market of the London Stock Exchange under the code IPO. |
![]() We invest in Brazilian pre-seed/seed stage startups developing sound products/solutions backed by superior technology teams. |
![]() IPV Capital Partners is a venture capital firm specializing in fund of funds, early stage and growth capital investments. It does not invest in the internet sector. The firm seeks to invest in software, new materials, semiconductors, technology services, advanced manufacturing, clean technology, medical technology, components and systems, network technologies, consumer electronics, high growth technology, and computing industries. It prefers to invest in companies based in China. IPV Capital Partners was founded in 2006 and is based in Shanghai, China with additional offices in Beijing, China; Shenzhen, China; and Palo Alto, United States. |
![]() LEAD is an accelerator and venture capital firm specializing in seed-stage, startups, pre-seed, early stage and growth capital investments. It seeks to make investments in lifestyle, teams, entertainment, health tech, sports tech sector with a focus on companies providing next-gen fan engagement and experience; solutions for connected athletes and communities; and startups in the derivative sports space, including eSports, new sports, and fantasy sports, healthcare, healthcare accessibility, youth sports, food as medicine, media/IP, women's health, orthopedics, wellness modalities, gaming sectors. The firm invests globally with Europe and US. It runs a 3-month program and accepts 10 teams. The finalists get funding up to €25,000 ($0.027 million) for a 8% equity stake. The firm takes minority stakes. LEAD was founded in February 2017 and is headquartered in Berlin, Germany. |
Blocore is a Web3-focused investment firm and builder that specializes in gaming, social, IP, and technology through in-house projects, joint ventures, and post-investment management. |
![]() We invest in early-stage game-changing technology companies in angel rounds, series seed and pre-series A.
VERSO X has a proprietary model for investing:
- $50,000 for 5.00% post-money
- 5x warrants or $250,000
- lead investor in next equity or debt round
VERSO X main selection criteria are:
- visionary yet execution-focused founders
- clear unit economics and business model
- proprietary tech and IP
VERSO X is ultimately:
- supportive of founders and their personal success
- focused on increasing support along the way
- engaged to deliver business advisory |
![]() CAPITAL 2B is venture capital firm specializing in seed/startups, early venture, pre-seed, seed and series A stages. It prefers to invest in tech and IP led sectors. The firm prefers to invest companies based in India. It prefers to invest equity investment between $ 0.2 million and $ 3 million. CAPITAL 2B is based in India. |
With over 29 years of investment history in the Asia Pacific market,the JAFCO Asia team brings excellence in venture capital management,backed by in-depth investment knowhow.JAFCO Asia’s focus is on high growth technology-related companiesin their early to growth-stage. Sectors favored include mobile and internet technology, consumer & services related, cyber security, medical/healthcare and renewable energy. JAFCO Asia also has an impressive track record of successful IPO, M&A and trade sale investment exits.With US$650 million funds under management currently (US$1.8 billion cumulative to date), we have invested in more than 480 companies and divested over 400 companies of which more than 110 have been publicly listed. In addition, the parent company of JAFCO Asia is JAFCO Co., Ltd, the largest venture capital company in Japan.As one of the most established VC firms in Japan for more than 40 years, JAFCO Tokyo has developed a wide range of deep business relationships with its prominent fund investors (LPs) comprising over 1,000 major Japanese brands looking for new business opportunities and partnerships in and outside Japan and also other parts of Asia. Based in Tokyo, the Asia Group of the Business Development Division supports investees very actively. Its members connect and mobilize LPs as well as utilize JAFCO’s reputable and resourceful network among industry leaders to achieve its mission to be an indispensable bridge for the portfolio companies to accelerate their growth, creating value and hence maximizing return for the funds.One of the masterpieces was the licensing of major Japanese animations to the largest video portal in China now known as Youku Tudou. The BD team was instrumental in Tudou obtaining exclusive rights from the intellectual property (IP) owners, thereby increasing the value of the company significantly. This arrangement has also subsequently become a practical standard for the industry acquiring IPs from Japan thereafter. |
![]() ABOUT USInvesting in the FutureOTB Ventures is a leading venture capital firm in the CEE investing in early growth, post-product, high-tech start-ups that are developing unique technologies. Our partners have each over 20 years of entrepreneurial and international venture capital experience, and a proven track record in supporting the expansion of start-ups across international markets. We believe that maintaining dialogue with founders is essential for us to effectively support them. We provide guidance, mentorship and advice, as well as strategic support and in-depth market knowledge. We utilize our industry, financial and personal networks - backed by our strong market reputation as a fair and founder-friendly investor. We're constantly searching for the next opportunity - and encourage ambitious, driven disruptors to reach out and get in touch with us.OTB Ventures is a venture capital fund investing in technology with unique IP, links to the CEE region, and global ambitions. We provide Series-A funding to empower entrepreneurs to scale their business globally, while retaining a strong focus on technology. |
PUK Ventures is the venture capital arm of Partnerships UK plc. It operate a £25m fund, investing in businesses with UK public sector sponsorship and strong commercial potential.Objective is enhance the value of assets, including technology and IP, created in UK public bodies such as universities and public sector research labs. |
![]() Category Agnostic, but we're into:
- IP & DATA
- HYBRIDS
- BREAKTHROUGHS
- EMERGING TRENDS
- NO BRAINERS
- No Code
- DeepTech
- FutureTech
- AI/AutoML
- Cannabis
- Chill Vibes |
We invest in IP driven or tech-enabled B2B solutions across most sectors. Proven market fit and consistent revenue growth over 12+ months is our starting point. Based in London we provide structured finance and private equity for growth, and we lead on investment rounds drawing additional capital from public and private capital markets including main-board and growth-stage stock exchanges in the UK, North America and Australia. |
![]() IQ Capital is a VC based in Cambridge & London. We invest in 'deep tech' early stage UK companies capable of dominating global markets. We are particularly focused on disruptive algorithms in data science / analytics, fintech, IoT as well as embedded systems including research machines and robotics.
Many of our investments have a strong link to innovation originating in Cambridge and we have made 22 investments in the last three years. Recent exits include trade sales to Oracle, Google, Apple, Huawei, BD and Xchanging as well as two IPOs.
We are currently investing up to £10m from our IQ Capital III Fund (2018 vintage) and we are actively seeking seed and Series A investments with rich deep tech IP at the core. |
![]() A successful technology transfer fund requires strong connections with research world to generate sound IP portfolio startups, an entrepreneurial ecosystem, capable of absorbing innovation and providing ancillary services and a dedicated team of highly skilled manager who understand the language of science and business. |
Proxy Ventures UK Ltd. is a private equity and venture capital specializing in pre-seed, seed, late seed, startup, and early stage investments. The firm seeks to invest in B2C startups, IP driven products, apps and market places. The firm typically invests in technology companies based in Europe, Finland. The firm invests its own money. Proxy Ventures UK Ltd. was founded in 2013 and is based in London, United Kingdom with additional office in London, United Kingdom and Punaauia, French Polynesia. |
![]() Double Rock is a San-Francisco based early-staged venture capital firm focused on enterprise and data-centric technologies, investing from seed to exit in companies with efficient business models and secure IP. |
![]() Martlet Capital Limited has invested in more than 50 start-ups, since its launch in 2011. We provide patient capital for early-stage IP rich, B2B deep technology and life science start-ups, with a primary focus on companies based in Cambridge.Our team is comprised of experienced investors and entrepreneurs. Initial sums of capital of £250K are invested to help support early-stage companies. Martlet will almost always co-invest with angels and seed funds and has the capacity to follow on in subsequent investment rounds. In addition to capital, we offer support, experience and a network of contacts.Martlet typically focuses on pre-seed and seed-stage companies. Potential investees must demonstrate their potential for rapid growth and will usually possess a strong defensible position with respect to their technology, intellectual property and products. In all cases, there must be a strong and demonstratable commercial demand for the technology under development.We have achieved several exits from our portfolio, from trade sales to global technology companies and IPO’s.Please visit our website to learn more. |
We take a unique approach to investments, and it has to do with the people in, behind, and associated with our firm. We make all investments as a team; every member of our firm is involved in every investment that we make. We seek the advice of a wide range of expert advisors. Our Limited Partners include both strategic partners (several large biotech and pharma companies) and qualified financial investors. We listen to our LPs and include their expertise in our diligence. We believe we make better decisions this way.venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams.We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.We seek out teams who are developing treatments that will have a meaningful impact on patient care. Our mission is to put our companies in the best possible position to succeed, by helping teams think through the best development plan to bring these therapies to patients.Founded in 2011, venBio’s venture funds comprise nearly $1 billion of committed capital. We are currently investing out of our third fund of approximately $394M committed capital. Our team combines scientific, clinical and operating experience in our investment decisions. |
Luminari Capital is a digital media fund focused on the innovation and disruption occurring globally throughout the video ecosystem. We partner with exceptional entrepreneurs, whom we believe are the next-generation luminaries in video, to help them build category-defining companies. In this next wave of evolution in video, where the predominant distribution modalities transition to IP and wireless, large incumbents will need to evolve their legacy businesses via 'build, partner, or buy' strategies. Concurrently, new entrants will emerge and will drive much of the key innovation. Many of these participants will be venture-backed, start-up companies. Some of these companies will become the next-generation leaders in the video ecosystem and achieve multi-billion dollar enterprise values. Luminari Capital believes that the firm is already invested in such companies, and we endeavor to invest in and partner with others. |
Parkwalk is one of the UK’s leading growth fund managers backing world-changing technologies emerging out of UK universities and research institutions with the aim of delivering world-class returns.We back high potential, hard science technology companies that aim to shape the future by commercialising innovation in sectors of strategic importance to UK Plc, such as AI, big data, life science, materials, cleantech, future of mobility, medtech and quantum computing.Parkwalk currently has over £250m of assets under management. We have invested in over 100 companies across our managed funds, including funds managed in conjunction with the universities of Oxford, Cambridge and Bristol.In 2017 Parkwalk joined forces with IP Group plc, a FTSE 250 listed company. |
![]() Silicon Catalyst is the world's only incubator and accelerator focused exclusively on the semiconductor industry, encompassing chips, chiplets, materials, intellectual property (IP), and silicon fabrication-based photonics, MEMS, sensors, life sciences, and quantum technologies. Established in 2015, the organization has engaged with over 1,200 semiconductor startups globally and admitted more than 100 companies into its 24-month customized incubation program. Each startup is closely guided by a Silicon Catalyst partner, benefiting from a semiconductor-focused curriculum and access to over 40 events worldwide annually.
The incubator's ecosystem offers comprehensive support, including in-kind services valued at over $150 million from partners such as TSMC, Synopsys, Arm, STMicroelectronics, MathWorks, and more. Strategic partners like Texas Instruments, ON Semiconductor, Soitec, Bosch, Cirrus Logic, Arm, STMicroelectronics, Sony, EMD Electronics, NXP, Mayfield, and GlobalFoundries actively participate in the selection process and seek collaboration opportunities with startups. Additionally, Silicon Catalyst has established a network of over 400 investors, including venture capitalists, angel groups, corporate VCs, and family offices, facilitating over $600 million in venture investments for its portfolio companies.
The organization also boasts a network of over 350 industry experts who provide tailored advisory services to meet the specific needs of each startup. Through these extensive resources and partnerships, Silicon Catalyst is dedicated to accelerating the success of semiconductor startups, driving innovation, and fostering the development of groundbreaking technologies in the semiconductor sector. |
![]() VGC is an early-stage private equity investor focused on the Attention Economy, backing B2B companies in Sports & Entertainment, Content & IP, and Marketing Services that shape how attention is acquired and monetised. |
![]() We invest in cross-border enterprise startups with strong IP doing $250K+ ARR |
Understanding IP investors
What are IP investors, and what do they look for?
Intellectual property as a focus covers two distinct populations: investors backing companies whose value rests substantially on patents, and those funding the services and infrastructure around intellectual property itself. The assessment differs completely, and founders should establish which conversation they are in. For patent-heavy companies, investors examine whether the protection covers the commercial product rather than an early research result. Claims that are narrow, easily designed around, or covering something adjacent to what you actually sell provide less defence than founders assume. Remaining patent life relative to your development timeline matters too, since protection expiring before a product reaches market is worth little. For services and infrastructure businesses, whether patent analytics, portfolio management, licensing platforms or litigation support, the questions are conventional software ones with a specialist customer. Investors assess whether law firms, corporate intellectual property departments and patent offices genuinely buy software, since these are conservative buyers with established tools and limited appetite for change. Freedom to operate is the third area and it applies to both. Investors will ask whether an independent assessment exists, particularly in densely patented fields where incumbents defend positions actively.
Why IP is attracting investor interest
Litigation finance and patent monetisation matured into a recognised asset class, which brought capital into a field that was previously the preserve of specialists. Investors funding claims against infringers, or acquiring portfolios to license, operate on returns uncorrelated with public markets, and that characteristic attracted institutional allocation. European patent architecture changed materially with the arrival of a unified court and a patent with unitary effect, which altered how protection is obtained and enforced across member states. That shift created demand for advice, tooling and strategy from companies whose existing arrangements were built around national filings. Volume and complexity grew alongside. Patent filings have increased while examination resources have not kept pace, which supports analytics and search tools that help offices, firms and companies work through larger portfolios. Machine learning changed what is possible in prior art search, classification and drafting support, and the field is document-heavy in ways that suit the technology. Investors are cautious about accuracy claims here, since errors in patent work carry professional liability, but the efficiency argument is real and the buyers have budgets.
Which funding stages IP investors are active at
Funding differs sharply between the two populations under this label. Patent-heavy operating companies raise on conventional stage patterns for their sector, with the intellectual property position examined as part of diligence rather than as the investment thesis. Deeptech, biotech and materials companies fall into this group. Intellectual property services and software companies follow enterprise stages, selling to law firms, corporate departments and patent offices. Seed rounds fund product and early adopters, Series A requires repeatable sales into a conservative buyer, and later rounds turn on retention within a customer base that changes tools reluctantly. Litigation finance and portfolio acquisition operate outside venture entirely, funded by specialist funds and institutional capital assessing individual claims or portfolios on their merits, with returns tied to case outcomes rather than company growth. Public funding across Europe supports patent filing costs for smaller companies through national schemes and European instruments, which is worth knowing since protection is expensive and the support meaningfully reduces the burden.
Types of investors active in IP
Investors backing companies where patents are central to defensibility. They commission freedom-to-operate assessments as a matter of routine and read claim scope critically rather than accepting that a granted patent equals protection.
Funds backing software sold to law firms and corporate intellectual property departments. They understand that these buyers are conservative, that procurement is slow, and that accuracy requirements are stricter than in general enterprise software.
Specialist capital funding infringement claims and portfolio enforcement, assessing case merits, jurisdiction and counterparty rather than company fundamentals. A distinct discipline that operates outside conventional venture entirely.
Capital acquiring and monetising portfolios, evaluating claim quality, remaining life and the commercial products the patents read on. They are potential buyers of intellectual property assets from companies that cannot commercialise them.
National and European programmes subsidising filing and prosecution costs for smaller companies. Not investors, but materially relevant since protection is expensive and these schemes reduce a real drain on early-stage cash.
Ready to reach IP investors?
Create a free CapLink account to unlock full investor profiles, contact details, ticket sizes and intelligent matching.
















